Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor

Cellular and Molecular Life Sciences

Volumn 62, Issue 15, 2005, Pages 1763-1771

  Krystof V ^a   McNae, I W ^b   Walkinshaw, M D ^b   Fischer, P M ^c   Muller P ^d   Vojtesek B ^d   Orsag M ^a   Havlicek L ^a   Strnad, M ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c CYCLACEL LTD   (United Kingdom)

^d MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

CDK9; Cyclin dependent kinase inhibitor; Olomoucine II; p53 mutation; Roscovitine; Transcription

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; OLOMOUCINE II; PROTEIN MDM2; PROTEIN P53; RIBOSOME PROTEIN; ROSCOVITINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME SPECIFICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; PROTEIN FUNCTION; RNA TRANSCRIPTION; TUMOR CELL LINE; WILD TYPE;

ANTINEOPLASTIC AGENTS; BINDING SITES; CDC2-CDC28 KINASES; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 2; ENZYME INHIBITORS; GROWTH INHIBITORS; HUMANS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; PURINES; RIBOSOMAL PROTEINS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 23844525170     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-005-5185-1     Document Type: Article

References (46)

1. Sherr C. J. (1996) Cancer cell cycles. Science 274: 1672-1677
2. Morgan D. O. (1995) Principles of CDK regulation. Nature 374: 131-134
3. Pinhero R., Liaw P., Bertens K. and Yankulov K. (2004) Three cyclin-dependent kinases preferentially phosphorylate different parts of the C-terminal domain of the large subunit of RNA polymerase II. Eur. J. Biochem. 5: 1004-1014
4. Meijer L. and Raymond E. (2003) Roscovitine and other purines as kinase inhibitors: from starfish oocytes to clinical trials. Acc. Chem. Res. 36: 417-425
5. Fischer P. M., Endicott J. and Meijer L. (2003) Cyclin-dependent kinase inhibitors. Prog. Cell Cycle Res. 5: 235-248
6. Vesely J., Havlicek L., Strnad M., Blow J. J., Donella-Deana A., Pinna L. et al. (1994) Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 224: 771-786
7. Havlicek L., Hanus J., Vesely J., Leclerc S., Meijer L., Shaw G. et al. (1997) Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J. Med. Chem. 40: 408-412
8. Gray N. S., Wodicka L., Thunnissen A. M., Norman T. C., Kwon S., Espinoza F. H. et al. (1998) Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281: 533-538
9. Krystof V., Lenobel R., Havlicek L., Kuzma M. and Strnad M. (2002) Synthesis and biological activity of olomoucine II. Bioorg. Med. Chem. Lett. 12: 3283-3286
10. Fischer P. M. and Gianella-Borradori A. (2003) CDK inhibitors in clinical development for the treatment of cancer. Expert Opin. Invest. Drugs 12: 955-970
11. Fischer P. M. and Gianella-Borradori A. (in press) Recent progress in the discovery and development of CDK inhibitors. Expert Opin. Invest. Drugs 14: 457-477
12. Sielecki T. M., Boylan J. F., Benfield P. A. and Trainor G. L. (2000) Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J. Med. Chem. 43: 1-18
13. David-Pfeuty T. (1999) Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells. Oncogene 18: 7409-7422
14. Wojciechowski J., Horky M., Gueorguieva M. and Wesierska-Gadek J. (2003) Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells. Int. J. Cancer 106: 486-495
15. Kotala V., Uldrijan S., Horky M., Trbusek M., Strnad M. and Vojtesek B. (2001) Potent induction of wild-type p53-dependent transcription in tumour cells by a synthetic inhibitor of eyelin-dependent kinases. Cell. Mol. Life Sci. 58: 1333-1339
16. Ljungman M. and Paulsen M. T. (2001) The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol. Pharmacol. 60: 785-789
17. Demidenko Z. N. and Blagosklonny M. V. (2004) Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res. 64: 3653-3660
18. Whittaker S. R., Wallon M. I., Garrett M. D. and Workman P. (2004) The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res. 64: 262-272
19. Azevedo W. F de. Jr, Canduri F. and Silveira N. J. da (2002) Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem. Biophys. Res. Commun. 293: 566-571
20. Schlosser I., Holzel M., Murnseer M., Burtscher H., Weidle U. H. and Eick D. (2003) A role for c-Myc in the regulation of ribosomal RNA processing. Nucleic Acids Res. 31: 6148-6156
21. Sirri V., Hernandez-Verdun D. and Roussel P. (2002) Cyclin-dependent kinases govern formation and maintenance of the nucleolus. J. Cell Biol. 156: 969-981
22. Wu S. Y., McNae I., Kontopidis G., McClue S. J., McInnes C., Stewart K. J. et al. (2003) Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Structure 11: 399-410
23. Leslie A. G. W. (1992) Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography 26
24. Vagin A. and Teplyakov A. (1997) MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 30: 1022-1025
25. Murshudov G. N., Vagin A. A. and Dodson E. J. (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Cryst. D 53: 240-255
26. Lamzin V. S. and Wilson K. S. (1997) Automated refinement for protein crystallography. Methods Enzymol. 277: 269-305
27. Jones T. A., Zou J. Y., Cowan S. W. and Kjeldgaard M. (1991) Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A Found. Crystallogr. A 47: 110-119
28. O'Connor P. M., Jackman J., Bae I., Myers T. G., Fan S., Mutoh M. et al. (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57: 4285-4300
29. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C. and Hainaut P. (2002) The IARC TP53 Database: new online mutation analysis and recommendations to users. Hum. Mutat. 19: 607-614
30. Vojtesek B., Bartek J., Midgley C. A. and Lane D. P. (1992) An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods 151: 237-244
31. Stephen C. W., Helminen P. and Lane D. P. (1995) Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J. Mol. Biol. 248: 58-78
32. Fredersdorf S., Milne A. W., Hall P. A. and Lu X. (1996) Characterization of a panel of novel anti-p21Waf1/Cip1 monoclonal antibodies and immunochemical analysis of p21Waf1/Cip1 expression in normal human tissues. Am. J. Pathol. 148: 825-835
33. Waseem N. H. and Lane D. P. (1990) Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA): structural conservation and the detection of a nucleolar form. J. Cell Sci. 96: 121-129
34. Chen J., Marechal V. and Levine A. J. (1993) Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13: 4107-4114
35. McClue S. J., Blake D., Clarke R., Cowan A., Cummings L., Fischer P. M. et al. (2002) In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer 102: 463-468
36. Schulze-Gahmen U., Brandsen J., Jones H. D., Morgan D. O., Meijer L., Vesely J. et al. (1995) Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins 22: 378-391
37. Dreyer M. K., Borcherding D. R., Dumont J. A., Peet N. P., Tsay J. T., Wright P. S. et al. (2000) Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717. J. Med. Chem. 44: 524-530
38. De Azevedo W. F., Leclerc S., Meijer L., Havlicek L., Strnad M. and Kim S. H. (1997) Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243: 518-526
39. Lichtenfels R., Biddison W. E., Schulz H., Vogt A. B. and Martin R. (1994) CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. J. Immunol. Methods 172: 227-239
40. Vermeulen K., Strnad M., Krystof V., Havlicek L., Van der Aa A., Lenjou M. et al. (2002) Antiproliferative effect of plant cytokinin analogues with an inhibitory activity on cyclin-dependent kinases. Leukemia 16: 299-305
41. Zhang Y., Wolf G. W., Bhat K., Jin A., Allio T., Burkhart W. A. et al. (2003) Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol. Cell. Biol. 23: 8902-8912
42. Chao S. H., Fujinaga K., Marion J. E., Taube R., Sausville E. A., Senderowicz A.M. et al. (2000) Flavopiridol inhibits P-TEFb and blocks HIV-1 replication J. Biol. Chem. 275: 28345-28348
43. Bhat K., Itahana K., Jin A. and Zhang Y. (2004) Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J. 23: 2402-2412
44. Rubi C. P. and Milner J. (2003) Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J. 22: 6068-6077
45. Ljungman M. and Lane D. P. (2004) Transcription - guarding the genome by sensing DNA damage. Nat. Rev. Cancer 4: 727-737
46. White R. J. (2004) RNA polymerase II transcription and cancer. Oncogene 23: 3208-3216